$3.040
-0.125 (-4.10%)收盤時
QNTM 資訊
QNTM 事件
Quantum BioPharma Receives FDA Approval for Lucid-MS to Enter Phase 2 Trials
Quantum BioPharma announced that the FDA has approved the company's investigational new drug, or IND, application for Lucid-MS, enabling Quantum BioPharma to immediately advance its patented multiple sclerosis program into Phase 2 clinical development. This will be the first time in history patients with MS consume the unique Lucid-MS new chemical entity molecule with a goal of reversing some or all of their loss of bodily control or mobility. Trial start-up activities, including site selection, are already underway, and the company expects to initiate patient enrollment and drug administration as quickly as possible.
QNTM Stock Trading Halted, News Pending
QNTM Stock trading halted, news pending
Quantum BioPharma Reaches Halfway Mark in Patient Enrollment with Massachusetts General Hospital
Quantum BioPharma announced a milestone in its collaborative study with Massachusetts General Hospital: patient enrollment has reached the halfway mark, accompanied by preliminary imaging results. This study is designed to validate a novel positron emission tomography imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis-a critical step toward transforming how disease progression and treatment response are measured.
Quantum BioPharma Submits FDA Application for Lucid-21-302
Quantum BioPharma announced that it has formally submitted an investigational new drug application to the FDA for Lucid-21-302, its new drug candidate for the treatment of multiple sclerosis.
Quantum BioPharma Signs LOI with Allucent to Support Lucid-MS Clinical Trial
Quantum BioPharma announced that it has entered into a binding letter of intent with Allucent to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis. The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS. Quantum BioPharma expects to initiate the Phase 2 trial in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operational arrangements. Under the terms of the LOI, Allucent will provide comprehensive clinical trial services designed to support efficient execution and data integrity throughout the study.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。